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Activation of peroxisome proliferator-activated receptors (PPARs), and particularly of PPARα and PPARγ, using selective agonists,
is currently used in the treatment of metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus. PPARα
and PPARγ anti-inﬂammatory, antiproliferative and antiangiogenic properties in cardiovascular cells were extensively clariﬁed
in a variety of in vitro and in vivo models. In contrast, the role of PPARδ in cardiovascular system is poorly understood.
Prostacyclin, the predominant prostanoid released by vascular cells, is a putative endogenous agonist for PPARδ, but only recently
PPARδ selective synthetic agonists were found, improving studies about the physiological and pathophysiological roles of PPARδ
activation. Recent reports suggest that the PPARδ activation may play a pivotal role to regulate inﬂammation, apoptosis, and
cell proliferation, suggesting that this transcriptional factor could become an interesting pharmacological target to regulate
cardiovascular cell apoptosis, proliferation, inﬂammation, and metabolism.
Copyright © 2009 Angela Tesse et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Peroxisome proliferator activated receptors (PPARs) are
transcriptional factors of intense interest through their
involvement in several biological processes such as energy
homeostasis, cell proliferation and diﬀerentiation, fatty acid
catabolism, and adipogenesis [1]. Among the three PPAR
isotypes identiﬁed, PPARα and PPARγ had been the most
extensively studied. PPARα is activated by several fatty acids
and expressed in tissues exhibiting a high rate of fatty acid
catabolism (liver, heart, kidney, and muscle). In the cardio-
vascular system, PPARα is expressed in cardiac and smooth
muscle cells, in endothelial cells and monocyte/macrophage
cells [2,3],anditregulatesfattyacidtransport,esteriﬁcation,
and oxidation, via activation of genes encoding key enzymes
involved in these processes [4]. We have also previously
described that the PPARα gene deletion induced defects of
the cardiac contractile performance and myocardial ﬁbrosis,
suggesting a major role of PPARα in the maintenance of
cardiovascular homeostasis within the physiological range
[5].
PPARγ is the most studied PPAR subtype, and is
primarily expressed in adipose tissue where it participates
in the transcription of various genes involved in lipid
metabolism, glucose homeostasis regulation, and in the
inﬂammatory processes, preventing foam cell formation [6]
and reducing nitric oxide (NO) overproduction, interleukin-
6 (IL-6), and tumor necrosis factor-α (TNF-α) expressions.
PPARγ activation suppresses cyclo-oxygenase-2 (COX-2)-
and inducible nitric oxide synthase (iNOS)-inductions by
repression of NF-κB and AP-1 [7, 8]. PPARγ can be activated
by synthetic agonists of the thiazolidinedione family, for
instance, rosiglitazone (RZ) [9], which is able to reduce
the inﬂammatory markers in diabetic patients [10]. Several
studies have shown that some eﬀects of PPARγ agonists are
PPARγ-independent [11, 12]. In contrast, we have recently
found a direct PPARγ-dependent protective action of RZ
on vascular dysfunction accompanying smooth muscle cell
inﬂammation. Indeed, selective PPARγ inhibitor, GW9662,
completelyabolishedthebeneﬁcialanti-inﬂammatoryeﬀects
of RZ [13].2 PPAR Research
PPARδ (also known as PPARβ and NR1C2) is the
most ubiquitously expressed, although its physiological and
pathological roles are unclear, especially in human tissues
[14, 15]. Prostacyclin, the predominant prostanoid released
by vascular cells, is a putative endogenous agonist for PPARδ
[16, 17]. The roles of PPARα and PPARγ in vascular cells
were extensively investigated in a variety of in vitro and
in vivo models, both having in general anti-inﬂammatory
and antiproliferative properties [18]. In contrast, the role of
PPARδ in cardiovascular functions is not fully understood
but there is a rising interest for this nuclear receptor in
this domain because of its pivotal role in apoptosis and
cell proliferation [19–21], and for its function as a key
regulator of fatty acid metabolism [22, 23]. On the light
of the recent data, in the present review, we focused our
attention on the new therapeutic approaches, using selective
agonists of PPARδ, to regulate cardiovascular function and
cardiac and vascular cell proliferations and apoptosis in
several cardiovascular pathologies.
2. PPARδ Agonists
Like other PPAR subtypes, PPARδ is activated by a large
variety of endogenous agonists, such as lipids, including
long-chain dietary fatty acids [23], and prostacyclin (PGI2)
[16,17].SyntheticanalogsofPGI2,suchascarbaprostacyclin
(cPGI2), are able to bind to and to act as agonists of PPARδ.
PPARα and PPARδ possess overlapping ligand speciﬁcities,
thus,fattyacidsandPGI2 analogshavebeenshowntoinduce
transcriptional activation and DNA binding of both PPAR
subtypes [24]. Moreover, stable prostacyclin analogs are able
to activate in vitro also PPARγ in a cell surface prostacyclin
receptor-dependent manner [25].
Moreover, several high-aﬃnity synthetic PPARδ ligands
were identiﬁed and have contributed to improve studies
about the physiological and pathophysiological roles of
PPARδ activation. These PPARδ activators include the
phenoxyacetic acid derivatives GW501516 and GW0742
(GlaxoSmithKline, Brentford, UK) [26], and L165041
(Merck, Whitehouse Station, NJ, USA) [27]. GW501516 and
GW0742 agonists show a thousand-fold PPARδ selectivity
over other PPAR subtypes [26] while L165041 has a weak
PPARγ binding activity at concentrations higher than 5μM
[27]. The PPARδ agonists have diﬀerent bioavailability and
eﬀects in the lipoprotein delivery system according to animal
models, primate, or mouse for instance [28]. There are
also two other synthetic agonists with high aﬃnity for
both PPARγ and PPARδ: L796449 and L165461 [27]. Now,
several new synthetic PPARδ agonists are in development for
clinicalapplications:MBX-8025(MetabolexInc,Calif,USA),
CER-002 (Cerenis Therapeutics, Mich, USA), and KD3010
(Kalypsys, Calif, USA) [29].
3. Role of PPARδ inCellApoptosisand
CellProliferation
Several reports showed that PPARδ activation by PGI2,i t s
analogues, or selective ligands, acutely regulates endothelial
cell apoptosis and protects endothelial cells from apoptosis
caused by oxidant stress [30], or induces human umbilical
endothelial cell (HUVEC) proliferation [19]. PPARδ activity
is also involved in a negative control of colorectal cancer
and keratinocyte cell apoptosis [31, 32]. Synthetic PGI2 has
beenshowntoprotectrenalcellsfromhypertonicity-induced
apoptosis, which was attributed to PPARδ activation [33].
More recently, it was found that endothelial cell survival was
improved in HUVECs transduced with an adenovirus con-
taining genes that selectively increased PGI2 synthesis [30].
Theauthorsrevealed,fortheﬁrsttime,thatPGI2 upregulates
14-3-3ε promoter activity in a PPARδ-dependent manner.
Indeed, 14-3-3ε upregulation leads to increase of BAD
binding and decreasing of BAD translocation to mitochon-
dria with subsequent inhibition of cytochrome c release,
caspase-3 activation and endothelial cell hydrogen peroxide
(H2O2)-induced apoptosis [30]. Furthermore, the PPARδ
overexpression ampliﬁes the antiapoptotic action of PGI2.
More recently, the mechanisms by which PPARδ agonists
control the 14-3-3ε expression were investigated and it was
suggested a key anti-inﬂammatory role of PPARδ activation
in promoting endothelial cell survival [34].
Itisknownthatreactiveoxygenspecies(ROS),mediators
of oxidative stress, play a deleterious role on vasculature
and myocardium. ROS and H2O2 have been reported to
induce apoptosis in various cell types. The role of PPARδ
activation using GW501516 was also investigated in H2O2-
induced apoptosis in rat cardiomyoblasts. PPARδ exerts
an antioxidant role in rat cardiac myoblasts by increasing
catalase expression in presence of H2O2 with a subsequent
cell protection from H2O2-induced apoptosis that is caspase-
3-dependent [35].
Concerning the cardiac injury and cardiomyocyte death
induced by ischemia, a recent study provides several lines of
evidence indicating a cardioprotective eﬀect of GW0742, via
upregulation of survival signalling and suppression of apop-
totic cell death. Indeed, GW0742 is able to reverse the detri-
mental eﬀect of ischemia/reperfusion on expression of Bcl
family genes. This reduces expression of proapoptotic genes,
Bax and Bid, and reverses the ischemia-dependent down-
regulation of the antiapoptotic gene, Bcl-xL [36]. More-
over, GW0742 treatment reduces the ischemia/reperfusion-
induced cardiac mitochondrial damage that is a critical step
in cell apoptotic death controlled by Bcl family proteins.
Activation of PPARδ by this agonist also reduces the
myocardial caspase-3 activity and increases cardiac p-Akt
and its upstream regulator, p-PDK, a central kinase for
signalling pathway regulating cell survival and cell growth
[37].
The role of PPARδ activation in cell proliferation is
somewhat controversial. Cardiac ﬁbroblast proliferation,
diﬀerentiation of ﬁbroblasts to myoﬁbroblasts, and collagen
synthesis were reduced after PPARδ activation [37]. It was
shown that a prostacyclin agonist, the beraprost sodium,
is able to enhance the PPARδ and iNOS expressions with
an antiproliferative eﬀect in rat aortic smooth muscle cells,
suggesting that iNOS is a downstream target of PPARδ
[38]. Moreover, suppression of PPARδ expression by RNAi
targeting signiﬁcantly promoted the proliferation of humanPPAR Research 3
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Figure 1: Eﬀects of PPARδ activation on potential targets implicated in cell death, cell proliferation, and inﬂammation. PPARδ can be
activated not selectively by endogenous agonists (EAs), such as several lipids, long-chain fatty acids (LCFAs), and prostacyclin (PGI2),
or synthetic agonists (SAs). PPARδ activation has an antiapoptotic eﬀect reducing reactive oxygen species (ROS), upregulating 14-3-3ε
activity and reducing cytochrome c release from mitochondria and subsequent caspase-3 activation. The eﬀect of PPARδ activation on cell
proliferation is cell type dependent. It has a proangiogenetic eﬀect in human umbilical endothelial cells (HUVECs), a proproliferative eﬀect
in keratinocytes (KCs), while an antiproliferative eﬀect in smooth muscle cells (SMCs) and in cardiac ﬁbroblasts (FBs) with subsequent
reduction of heart ﬁbrosis. PPARδ activation in endothelial progenitor cells (EPCs) enhances vasculogenesis. PPARδ has anti-inﬂammatory
eﬀects by reducing cytokines production and molecules implicated in endothelial/leukocyte interactions.
colorectal cancer cells (HCT-116) by increasing the number
of cells in G1 phase [39]. In contrast, in another work,
Zeng et al. have shown that PPARδ is able to induce
cell proliferation in human thyroid tumors by regulating
epithelial cell proliferation via cyclin E1, growth factor and
lipid signals. Moreover, PPARδ is upregulated in human
thyroid tumors and the deregulation of the PPARδ/cyclin E1
pathway may be important not only in thyroid cancer but
also in other types of carcinomas [40]. PPARδ expression
and activation were rapidly stimulated by epidermal growth
factor (EGF) stimuli in HaCaT keratinocytes and this
promoted cell proliferation [41]. PPARδ-/- mice exhibit
increased keratinocyte proliferation when treated with a
tumor promoter [42]. On the light of these new studies,
the eﬀects of PPARδ activation on cell proliferation seem
to be cell type speciﬁc. PPARδ roles in apoptosis and cell
proliferation are synthesized in Figure 1.
4. PPARδ inAngiogenesis andVasculogenesis
PPARδ activation could play an important role also in vascu-
lar growth, in particular in vasculogenesis from endothelial
progenitor cells (EPCs) and angiogenesis deriving from pre-
existing endothelial cells [43]. A recent study showed that
PPARδ activation, using GW501516, induces cell prolifera-
tion in human endothelial cell cultures and angiogenesis in
a murine Matrigel plug assay in vivo through a mechanism
that involves vascular endothelium growth factor (VEGF)
gene transcription. Moreover, the same study showed that
GW501516 is able to induce transcription of PPARδ target
genes such as the adipose diﬀerentiation-related protein
(ADRP), VEGF, and the matrix metalloproteinase-9. These
data suggest that endogenous prostacyclin, like the synthetic
agonist GW501516, may regulate endothelial cell prolifera-
tion and angiogenesis through a PPARδ-dependent VEGF
gene expression [19].
PPARδ activationwithagonists,GW501516orL-165041,
increased the proliferation of human early EPCs and pro-
tected them from hypoxia-induced apoptosis. In addition,
PPARδ activation enhanced EPC transendothelial migration
and tube formation [44]. Injection of the GW501516-treated
human or mouse early EPCs, in a hind limb ischemia
model of athymic nude mice, signiﬁcantly accelerated limb
perfusion improvement after 21 days of ischemia. This was
associated with an increased capillary density determined
by histological studies. PPARδ agonist-treated EPCs from
PPAR-δ-/- mice failed to enhance vasculogenesis. These
ﬁndings suggest that ex vivo activation of PPARδ in early
EPCs results in enhanced vasculogenic potential in vivo,4 PPAR Research
and this was conﬁrmed also in a corneal neovascularization
model [43]. The beneﬁcial eﬀects observed after PPARδ
activation in EPCs are mediated by the PIK/Akt pathway
implicated in vasculogenesis [45–47]. More recently, He and
coworkers provided evidences that the proangiogenic eﬀects
of human late EPCs are partially dependent on biosynthesis
and release of PGI2 and subsequent PPARδ activation
[48]. Indeed, in the same study, the downregulation of
PPARδ expression impaired in vivo angiogenesis in nude
mice transplanted with EPCs, treated with COX-1 or PGI2
synthase (PGIS) small interfering RNAs, supporting the
concept that the COX-1/PGI2/PPARδ pathway in human
EPCs plays an important role in angiogenesis [48].
Interestingly, a tumor vascularization defect was found
in PPARδ-/- mice with subsequent decreased progression
and partial regression of tumors in this mouse model. This
was due to the abundance of highly abnormal hyperplas-
tic microvessels appearing dysfunctional in tumors from
PPARδ-/- mice [49]. Even though a defect in angiogenesis
has not been observed during normal development of
PPARδ-/- mice, PPARδ is speciﬁcally required by tumor
endothelial cells to orchestrate their proliferation and diﬀer-
entiation in an environment providing abnormal sources of
growth factors and cytokines [49]. These ﬁndings suggest an
interesting potential for clinical applications of PPARδ as a
target in the tumor treatment.
5. Role of PPARδ in Atherosclerosis
The atheroprotective role of PPARδ activation remains
controversial. The PPARδ activation using GW0742 reduces
only weakly atherosclerosis formation in mice knockout for
the low-density lipoprotein receptor (LDLR) gene [50]. In
another study, administration of the same agonist at a lower
dose failed to have an eﬀect in foam cell formation and in
vascular lesions in the same mouse model [51]. The limited
atheroprotective eﬀect of GW0742 might be explained
through its inability to modify high-density lipoprotein
cholesterol (HDL-c) levels in both studies.
Besides, more recently, it was conﬁrmed a vascu-
lar protective eﬀect of PPARδ activation in a model of
angiotensin II (Ang II)-induced atherosclerosis in LDLR-/-
mice. The authors evidenced attenuated Ang II-accelerated
atherosclerosis through the increased expression of the
anti-inﬂammatory corepressor, B cell lymphoma-6 (Bcl-
6). Furthermore, Ang II activation of MAP kinases (p38
and ERK1/2) was inhibited in LDLR-/- mice infused with
Ang II and treated with a high-fat diet supplemented with
GW0742 [52]. Another selective PPARδ agonist, GW501516,
has been reported to reduce atherosclerotic lesion formation
in ApoE-/- mice submitted to high-fat diet [53]. This agonist
was able to improve HDL-c blood levels in these mice in
agreement with results previously obtained in monkeys [54].
Indeed,GW501516promotesreversecholesteroltransportin
macrophages, a key step in reducing foam cell formation, by
increasing expression of the reverse cholesterol ATP-binding
cassette transporter A1. This agonist also causes a dramatic
dose-dependentriseofHDL-c,whileitdecreasesthelevelsof
LDLs in serum of obese Rhesus monkeys [54]. PPARδ ago-
nists may also possess antiatherosclerotic properties in vivo
by decreasing the amount of nonliganded PPARδ receptor
and by releasing the transcriptional repressor Bcl-6 of foam
cells [55]. Furthermore, in the work of Barish et al. [53],
DNA array and real-time PCR analyses, conducted in aortas
from GW501516-treated ApoE-/- mice, have evidenced
potential PPARδ target genes. Experiences have shown a
downregulation of both CXCL7 and CCL21α, implicated
in neutrophil and T lymphocyte recruitment induction. In
contrast, others proteins were upregulated, in particular the
regulators of G protein signalling (RGS) 4 and 5, which
antagonize the signalling mediated by the chemokine recep-
tors. The tissue inhibitor of metalloproteinase 3 (TIMP3),
implicated in smooth muscle cell migration and lesion
stability, was also upregulated. At last, chemokine expression
was downregulated by GW501516, conﬁrming the anti-
inﬂammatory property of PPARδ activation [53].
Endothelial cell monolayer is exposed to circulating
inﬂammatory factors that predispose to atherosclerosis.
Increasing evidences suggest that the endothelial cell apop-
tosis might contribute to the development of atherosclerosis
and acute coronary syndromes [55]. PPARδ agonists might
modulate the development of atherosclerosis and acutecoro-
nary syndrome, not only by targeting foam cells and lipopro-
tein metabolism [56, 57], or protecting against obesity [58],
but also by promoting endothelial cell survival via 14-3-3ε
[34]. Indeed, 14-3-3 and 14-3-3ε proteins are antiapoptotic
and anti-inﬂammatory molecules in endothelial cells and
theymayplayanimportantroleinatherothrombosis[30,59,
60].Inparticular,14-3-3proteinsmodulatecrucialaspectsof
heart function both in and in vivo [60–63]. In a recent study,
GW0742 and GW501516 signiﬁcantly inhibit the vascular
cell adhesion molecule 1 (VCAM-1) and E-selectin expres-
sions induced by TNFα, ensuing in reduced endothelial-
leukocyte adhesion in HUVECs. Moreover, PPARδ activa-
tion upregulates expression of antioxidative genes such as
superoxide dismutase 1, catalase, and thioredoxin, leading
to a reduced ROS production in endothelial cells [64].
These studies suggest the protective role played by PPARδ in
the regulation of multiple proinﬂammatory pathways with
subsequent atherosclerosis suppression.
6. Role of PPARδ inCardiacProtection
PPARδ is the predominant PPAR subtype in cardiac cells and
it is implicated in the regulation of cardiac lipid metabolism,
suggesting its important role in cardiac diseases. Indeed,
mice with cardiac-speciﬁc deletion of the PPARδ gene devel-
oped myocardial lipid accumulation and cardiomyopathy
[65].
The inﬂammatory response following cardiac ischemia/
reperfusion is a determinant factor responsible for tissue
injury development triggered by the cytokine cascade and
the upregulation of adhesion molecules and chemokines.
These events enhanced neutrophil and monocyte inﬁltra-
tions into myocardium and lead to cardiac damage [66].
The PPARδ activation by GW0742 reduces inﬂammatoryPPAR Research 5
cytokine expression, ending up in a reduction of plasma
levels of some interleukins (IL-6 and IL-8). Furthermore,
GW0742 is able to decrease expression of the adhesion
molecule for leukocytes, ICAM-1, and of the chemokine
responsible for monocyte recruitment, MCP-1, in a cardiac
ischemia/reperfusion model [36].
Diabetespredisposestoheartfailure,particularlyincom-
bination with other comorbid conditions such as hyperten-
sion and coronary artery disease [67]. The incidence of heart
failure and death, following myocardial infarction, is higher
in diabetic than in nondiabetic individuals [68]. PPARα and
PPARδ drive distinct cardiac metabolic regulatory programs
inmousemodelsoftype2diabetes.Indeed,PPARδ activates,
whereas PPARα represses, targets involved in the cellular
glucose utilization, resulting in reciprocal eﬀects on cellular
glucose uptake through diﬀerential regulation of glucose
transporter 4 (GLU4/SLC2A4) transcription. These ﬁndings
suggest that cardiac speciﬁc overexpression of PPARδ is
cardioprotective in diabetes [22].
The development of heart failure is also associated with
extensive ﬁbrosis, which aggravates diastolic dysfunction
and predisposes to arrhythmias [69, 70]. A critical event
in ﬁbrosis initiation is the proliferation and diﬀerentia-
tion of cardiac ﬁbroblasts. Upon activation by cytokines,
growth factors, or stretch, ﬁbroblasts start their prolifer-
ation and ultimately diﬀerentiate towards myoﬁbroblasts,
acquiring smooth muscle-like properties [71, 72]. Although
ﬁbroblasts take care of normal collagen turnover [73],
myoﬁbroblasts are rather responsible for the alteration of
extracellular matrix accumulation, often leading to impaired
organ function [54]. PPARδ activation leads to reduced
cardiac ﬁbroblast proliferation by a mechanism that involves
the upregulation of PPAR-responsive cell cycle inhibitory
G0S2 gene [37]. Moreover, heart collagen is inhibited
after PPARδ activation. These ﬁndings are in agreement
with another work, in which it was found a protective
eﬀect of PPARδ activation by GW501516 in the inhibi-
tion of Ang II-induced collagen type I expression via a
decreased collagen synthesis in adult rat cardiac ﬁbroblasts
[74].
In the transitions from foetal to neonatal and to adult
life, cardiac metabolism switches from glucose to fatty
acids as a preferred energetic substrate to generate ATP
[75]. In contrast, cardiac hypertrophy is associated with an
increase in glucose utilization and a decrease in fatty acid
oxidation [76]. It was found that the PPARδ activation by L-
165041 inhibits the phenylephrine-induced hypertrophy in
neonatal rat cardiac myocytes. The target is NF-κB signalling
pathwaythatplaysapivotalroleinthehypertrophicresponse
of cultured cardiac myocytes [77]. Moreover, hypertrophy
in neonatal rat cardiomyocytes caused a reduction in
expression of pyruvate dehydrogenase kinase 4 (Pdk4), a
target gene of PPARδ involved in fatty acid utilization.
Indeed, NF-κB activation, during cardiac hypertrophy,
downregulates PPARδ activity, leading to a fall in fatty acid
oxidation, through a mechanism that involves enhanced
protein-protein interactions between the p65 subunit of NF-
κBa n dP P A R δ and a subsequent reduction on expression
of PPARδ target genes [23]. On the basis of the literature,
one can think that several therapeutic approaches using
PPARδ agonists may be possible to treat vascular and cardiac
pathological states, especially those in which inﬂammation,
ﬁbrosis, and lipid metabolic disorders are involved. The
eﬀects of PPARδ activation on cardiac cells are synthesized
in Figure 1.
7. Role of PPARδ Activationin
Metabolic Diseases
High-fat diet, a sedentary way of life, and genetic factors
seem to account for the development of cardiovascular
diseases, including atherosclerosis and heart stroke. At
the same time, obesity is an important risk factor for
cardiovascular disorders, since it is often associated with
hypertension and increases the risk of metabolic disorders
such as insulin resistance, hypertriglyceridemia and low
plasmatic levels of HDL-c. Patients characterized by these
metabolicabnormalitiesmaybeconsideredasaﬀectedbythe
metabolic syndrome. PPARδ is involved in lipid metabolism
control and energy homeostasis [78]. The PPARδ activation
promotes fatty acid catabolism in several tissues, such as
skeletal muscles and adipose tissue [57, 79]. Moreover,
several recent studies suggest a potential role of PPARδ in
the regulation of glucose metabolism and insulin sensitivity
[80]. PPARδ agonists have advantageous eﬀects in obesity
prevention and modulation of lipoprotein metabolism [54,
57, 58]. Indeed, transgenic mice overexpressing PPARδ are
protected against diet-induced obesity through an increased
catabolism of fatty acids [58]. Moreover, administration of
PPARδ agoniststomicetreatedwithahigh-fatdietdecreased
insulin resistance by enhancing fatty acid oxidation and
decreasing lipid content of skeletal muscles [57].
Pharmacological activation of PPARδ, using GW0742,
protects heart from ischemia/reperfusion injury in male
Zucker fatty rats, a rodent model of obesity and dyslipidemia
[36]. All these studies suggest a protective eﬀect of PPARδ
activation in the cardiovascular complications induced by
metabolic disorders.
8. Conclusion
PPARδ activation is presently used as a new therapeutic
approach in several metabolic and cardiovascular patho-
logical states. PPARδ activators are in development for the
treatment of dyslipidemia, obesity and/or insulin resistance
in patients with the metabolic syndrome [78]. PPARδ
agonists have advantageous eﬀects in obesity prevention
and modulation of lipoprotein metabolism [54, 57, 58].
GW501516 was tested for its eﬀects on dyslipidemia in
obese Rhesus monkeys. This agonist increased of 79% HDL-
c and decreased of 56% and of 29% plasmatic levels of
triglycerides and LDL-c, respectively [54] .T h es a m ea g o n i s t
increased HDL-c, apolipoprotein A-1, and apolipoprotein
A-2 in vervet monkeys, a primate atherosclerosis model
[81]. The results of the ﬁrst human trial, conducted with a
small cohort of healthy volunteers, have shown no toxicity
during a treatment period of two weeks with GW5015166 PPAR Research
at the doses used for this study [82]. GW501516 has
been in a phase II clinical safety/eﬃcacy study for dys-
lipidemia, completed in October 2008 by GlaxoSmithKline.
The results of this study have not been published yet. The
use of GW501516 could be also a promising therapeutic
approach to prevent multiple aspects of the cardiac ﬁbrotic
process [37, 60]. PPARδ activation and/or overexpression,
improving increased glucose use in diabetic heart, shows
promises as a therapeutic strategy for cardiac dysfunction
caused by diabetes and ischemia [22]. Furthermore, the
use of GW0742 may be a new pharmacological approach
to protect patients aﬀected by metabolic syndrome from
their elevated risk of ischemic heart disease. GW0742
decreases lipotoxicity, inﬂammation, and upregulates cell
survival [36]. GW0742 and GW501516 could be also used
to treat inﬂammatory diseases such as atherosclerosis and
diabetes [64].
MBX-8025 is one of the most advanced PPARδ agonists
currently in a phase II clinical trial for dyslipidemia and in
particular for its eﬀects on lipid and metabolic parameters,
including triglycerides, LDL and HDL-c, insulin sensitivity,
and inﬂammation. This drug was administrated alone or
in association with Lipitor (atorvastatin, Pﬁzer Inc., NY,
USA), to patients aﬀected by metabolic syndrome. MBX-
8025depletedsubstantiallythesmall,dense,LDL-cholesterol
particles, alone or in combination with Lipitor. Other
second-generation PPARδ agonists, CER-002 and KD3010,
are in phase I clinical trial for atherosclerosis and metabolic
disorder treatments, respectively [29].
Recombinant adenovirus, bearing a gene that selec-
tively increases PGI2 synthesis and subsequent PPARδ
activation, has been shown to protect neurons from
ischemia/reperfusion in vivo in a model of ischemic cerebral
infarction [83]. This could be attributed to the antiapoptotic
action of PGI2. Gene transfer may be used as a new potential
treatment for protecting blood vessels during ischemic
diseases through reduction of the vascular cell death.
On the light of these recent ﬁndings, we can aﬃrm that
PPARδ regulation by appropriate selective agonists, as well
as PPARα and PPARγ activation, could be used as a novel
therapeutic intervention in metabolic and cardiovascular
inﬂammatory diseases through its eﬀect in atherogenesis
control and angiogenesis regulation. Nevertheless, the long-
term use of PPARδ ligands in patients susceptible to angio-
genicdiseases,suchasdiabeticswhoarepronetoretinopathy
or individuals predisposed to cancer, may require particular
care and a better understanding of its possible collateral
eﬀects.
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